PLA2G7 and congestive heart failure: Clinical studies, in vivo pharmacodynamics and metabolomics revealed the following findings: 1) QWQX І improved cardiac function and cardiac remodeling; 2) metabolite enrichment analysis suggested that glycerophospholipid metabolism and taurine and hypotaurine metabolism were the potential pathways for CHF therapy of QWQX I; 3) KEGG analysis showed that Lp-PLA2 is a key metabolic enzyme regulated by QWQX I in CHF.